A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet
- PMID: 29288545
- DOI: 10.1002/oby.22081
A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet
Abstract
Objective: Improving the maintenance of lost weight remains a critical challenge, which can be addressed by long-term behavioral and/or pharmacological interventions.
Methods: This study investigated the efficacy of combined behavioral and pharmacological treatment in facilitating weight loss maintenance (WLM) in 137 adults (86.1% female; 68.6% black; BMI = 37.0 ± 5.6 kg/m2 ) who had lost ≥ 5% of initial weight during a 14-week low-calorie diet (LCD) program (mean = 9.3 ± 2.9%). Participants were randomly assigned to lorcaserin (10 mg twice a day) or placebo and were provided 16 group WLM counseling sessions over 52 weeks.
Results: At 24 weeks post randomization, more lorcaserin-treated than placebo-treated participants maintained a ≥ 5% loss (73.9% vs. 57.4%; P = 0.033), and the lorcaserin-treated participants lost an additional 2.4 ± 0.8 kg versus a 0.6 ± 0.8 kg gain for placebo (P = 0.010). However, at week 52, groups did not differ on either co-primary outcome; 55.1% and 42.6%, respectively, maintained ≥ 5% loss (P = 0.110), with gains from randomization of 2.0 ± 0.8 kg and 2.5 ± 0.8 kg (P = 0.630), respectively. From the start of the LCD, groups maintained reductions of 7.8% and 6.6%, respectively (P = 0.318).
Conclusions: Combined behavioral and pharmacological treatment produced clinically meaningful long-term weight loss in this group of predominantly black participants. Lorcaserin initially improved upon weight loss achieved with WLM counseling, but this advantage was not maintained at 1 year.
Trial registration: ClinicalTrials.gov NCT02388568.
© 2017 The Obesity Society.
Similar articles
-
A randomized controlled trial of lorcaserin and lifestyle counselling for weight loss maintenance: changes in emotion- and stress-related eating, food cravings and appetite.Clin Obes. 2018 Dec;8(6):383-390. doi: 10.1111/cob.12279. Epub 2018 Sep 17. Clin Obes. 2018. PMID: 30222916 Free PMC article. Clinical Trial.
-
Lorcaserin plus lifestyle modification for weight loss maintenance: Rationale and design for a randomized controlled trial.Contemp Clin Trials. 2017 Aug;59:105-112. doi: 10.1016/j.cct.2017.06.004. Epub 2017 Jun 16. Contemp Clin Trials. 2017. PMID: 28600158 Clinical Trial.
-
Short- and Long-Term Changes in Health-Related Quality of Life with Weight Loss: Results from a Randomized Controlled Trial.Obesity (Silver Spring). 2018 Jun;26(6):985-991. doi: 10.1002/oby.22187. Epub 2018 Apr 20. Obesity (Silver Spring). 2018. PMID: 29676530 Free PMC article. Clinical Trial.
-
Lorcaserin: an investigational serotonin 2C agonist for weight loss.Am J Health Syst Pharm. 2011 Nov 1;68(21):2029-37. doi: 10.2146/ajhp100638. Am J Health Syst Pharm. 2011. PMID: 22011982 Review.
-
Evaluation of lorcaserin for the treatment of obesity.Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):1053-9. doi: 10.1517/17425255.2013.798643. Epub 2013 Jun 26. Expert Opin Drug Metab Toxicol. 2013. PMID: 23802690 Review.
Cited by
-
"Last Supper" Predicts Greater Weight Loss Early in Obesity Treatment, but Not Enough to Offset Initial Gains.Front Psychol. 2018 Aug 2;9:1335. doi: 10.3389/fpsyg.2018.01335. eCollection 2018. Front Psychol. 2018. PMID: 30116212 Free PMC article.
-
Mindful Eating, General Mindful Awareness, and Acceptance as Predictors of Weight Loss.Mindfulness (N Y). 2020 Dec;11(12):2818-2827. doi: 10.1007/s12671-020-01493-5. Epub 2020 Sep 18. Mindfulness (N Y). 2020. PMID: 33777254 Free PMC article.
-
A randomized controlled trial of lorcaserin and lifestyle counselling for weight loss maintenance: changes in emotion- and stress-related eating, food cravings and appetite.Clin Obes. 2018 Dec;8(6):383-390. doi: 10.1111/cob.12279. Epub 2018 Sep 17. Clin Obes. 2018. PMID: 30222916 Free PMC article. Clinical Trial.
-
"Anti-obesity medications" or "medications to treat obesity" instead of "weight loss drugs" - why language matters - an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM).Arch Endocrinol Metab. 2023 Aug 16;67(4):e230174. doi: 10.20945/2359-4292-2023-0174. Arch Endocrinol Metab. 2023. PMID: 37585688 Free PMC article.
-
Long-term effects of weight-reducing drugs in people with hypertension.Cochrane Database Syst Rev. 2021 Jan 17;1(1):CD007654. doi: 10.1002/14651858.CD007654.pub5. Cochrane Database Syst Rev. 2021. PMID: 33454957 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical